Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) COO Christina Rossi sold 2,274 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $95.91, for a total value of $218,099.34. Following the transaction, the chief operating officer now owns 69,383 shares of the company's stock, valued at $6,654,523.53. This represents a 3.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Christina Rossi also recently made the following trade(s):
NASDAQ BPMC traded up $1.21 on Friday, reaching $90.14. 1,266,828 shares of the stock traded hands, compared to its average volume of 690,804. Blueprint Medicines Co. has a 12 month low of $72.24 and a 12 month high of $121.90. The company has a market cap of $5.73 billion, a price-to-earnings ratio of -42.72 and a beta of 0.59. The company has a fifty day moving average price of $92.45 and a 200-day moving average price of $97.23. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32.
Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The firm had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. During the same period in the previous year, the company posted ($2.20) earnings per share. The firm's quarterly revenue was up 126.5% on a year-over-year basis. As a group, research analysts forecast that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.
Hedge funds have recently bought and sold shares of the stock. Quarry LP purchased a new position in shares of Blueprint Medicines in the 3rd quarter valued at $32,000. Covestor Ltd grew its position in shares of Blueprint Medicines by 206.7% in the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company's stock worth $55,000 after buying an additional 403 shares during the last quarter. Quantbot Technologies LP purchased a new position in Blueprint Medicines in the third quarter worth $108,000. Van ECK Associates Corp increased its position in shares of Blueprint Medicines by 13.3% during the second quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock worth $120,000 after purchasing an additional 131 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new stake in shares of Blueprint Medicines during the 3rd quarter valued at $122,000.
Several brokerages have recently issued reports on BPMC. HC Wainwright restated a "buy" rating and set a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, November 15th. Guggenheim reaffirmed a "buy" rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. UBS Group began coverage on Blueprint Medicines in a report on Thursday, October 24th. They issued a "neutral" rating and a $88.00 target price for the company. Wedbush restated an "outperform" rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Thursday, November 14th. Finally, Wells Fargo & Company dropped their price objective on shares of Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating for the company in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $122.11.
View Our Latest Report on Blueprint Medicines
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Blueprint Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Blueprint Medicines wasn't on the list.
While Blueprint Medicines currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.